Market Scope

Market Scope surveyed ophthalmologists and optometrists in the US and Western Europe during July and August 2024 to measure patients they were seeing and screening for ocular surface disease; adoption of treatments; and insight into the latest market trends. When asked to rank the top dry eye treatment options based on the efficacy levels they provide, ophthalmologists in the United States reported high marks for over-the-counter lubricants, steroids, lid hygiene, and punctal plugs. US optometrists, on the other hand, ranked intense pulse light and in-office thermal expression devices first and second—but agreed with their MD counterparts on lid hygiene and punctal plugs as the third and fourth most efficacious. Other questions in this survey probed the prevalence of types of ocular surface disease; dry eye severity and pathology; allergic conjunctivitis treatments; diagnostic technologies and procedures used to diagnose different ocular surface conditions; and the drops, devices, alternative treatments, and biologics used for dry eye. The aggregate results from this survey are presented in Market Scope's "2024 Ocular Surface Disease Survey Report." This report includes breakouts for the MDs versus ODs in the United States and separate analysis for MDs in Western Europe. This survey report was designed to help market competitors better understand industry dynamics, gain important insights into leading trends, and explore providers' adoption of new treatments and their plans to invest in equipment. To learn more about this report and request a sample: ?? https://bit.ly/24OSD ?? [email protected] #OcularSurfaceDisease #DryEye #Treatment #Diagnostic #SurveyResults #MarketIntelligence #MarketDynamics #PurchasingPlans #EyeCare #Ophthalmologists #Optometrists

Weekly Ophthalmic News Update – the latest news & trends you need to know: Sandoz Gains EU Approval for its Aflibercept Biosimilar Known as Afqlir: https://bit.ly/3Ofcnqz Q3-2024 Ophthalmic Revenue Roundup for Alcon, Hoya, RxSight, Inc., Sight Sciences, and Iridex: https://bit.ly/4fPHg0w Eyenovia, Inc. Scraps Phase III Study of Low-Dose Atropine in Myopia After Endpoint Missed: https://bit.ly/3AOitew Kalaris Therapeutics Will Merge with AlloVir and Advance Candidate for Exudative Retinal Disease: https://bit.ly/40RYAOj Advancium Health Network Signs Option to License Retinoblastoma Candidate from Aileron Therapeutics: https://bit.ly/4fvEk9n Arctic Vision Ltd. Licenses Chinese Rights for Xipere to Santen for $85 Million: https://bit.ly/3V07XaW US FDA Grants Fast Track Designation to FELIQS’ ROP Candidate: https://bit.ly/3Z7UYGt Register for free on Market-Scope.com to read more ophthalmic news: https://buff.ly/3mmLOlG #Ophthalmology #Ophthalmic #News #Revenues #Cataract #Glaucoma #Retina #Refractive #Cornea #Surgical #Pharma

There is increasing evidence that microstents are achieving substantial drops in IOP over a long period of time. Devices in various stages of development and commercialization have been able to maintain IOP below 15 mmHg and, in many instances, achieve IOP reductions of 30?to 40?percent. Given that these surgical procedures are relatively easy to perform and have minimal complications or aftercare, Market Scope sees momentum building for the paradigm shift that would mean earlier surgical intervention in glaucoma, as companies seek approval for standalone glaucoma procedures. Microstents capable of consistently achieving IOP in the range of 15 mmHg to 18 mmHg are most often targeting glaucoma patients in a mild stage of disease, including cataract surgery patients with mild glaucoma. The goal is a very safe and easy-to-perform surgical procedure that reduces or eliminates a patient’s needs for medication that controls IOP. The greatest adoption of microstents has been in the United States market, where implanted microstents have increased from 5 thousand in 2012 and are projected to grow to nearly 225 thousand in 2024. A decline in CMS microstent reimbursement beginning in 2022 created headwinds for device makers, but two factors will fuel healthy future growth in the market: Alcon, the world’s leading ophthalmic device company, driving sales of the Hydrus Microstent technology after acquiring Ivantis in 2021; and companies adding microstents designed for more advanced and standalone patients. Market Scope’s new “2024 Glaucoma Surgical Device Market Report” offers a comprehensive analysis of the current global market for glaucoma devices, as well as a discussion of important trends, an examination of upcoming products that will impact the market, and a review of other key factors shaping future success.? This new report offers a comprehensive analysis of the current global market for glaucoma devices, as well as a discussion of important trends, an examination of upcoming products that will impact the market, and a review of other key factors shaping future success.?Product demand is forecast in units and dollars, and market shares are analyzed by product category. Twenty-two market competitors are profiled, with discussion of their products, strategic market position, background, and outlook. To learn more about this report and request a sample: ?? https://bit.ly/24GlDev ?? [email protected] #Microstents #Glaucoma #Surgery #Device #Ophthalmology

Weekly Ophthalmic News Update – the latest news & trends you need to know: US FDA Grants De Novo Classification to LumiThera, Inc.’s Photobiomodulation System for Dry AMD: https://bit.ly/3O4MNEK Q3-2024 Ophthalmic Revenue Roundup for AbbVie, Apellis Pharmaceuticals, Glaukos Corporation, STAAR Surgical, and LENSAR, Inc.: https://bit.ly/3Azmqnc NovaBay Pharmaceuticals Accepts Higher Offer from PRN to Purchase Assets: https://bit.ly/3Z0gPPZ US FDA Asks for Added Data on Neurotech Pharmaceuticals, Inc.'s MacTel Candidate, Pushes Back PDUFA Date: https://bit.ly/4esmByi US FDA Gives Green Light to Phase I Trial of HuidaGene Therapeutics ’ CRISPR RNA-Editing Candidate for Wet AMD: https://bit.ly/4esv0Sx DáVI - Farmacêutica Licenses Clobetasol Propionate Post-op Drops from Formosa Pharmaceuticals, Inc. for Portugal: https://bit.ly/4evArQt Tarsus Pharmaceuticals, Inc. Appoints Elizabeth Yeu, MD, as Chief Medical Officer: https://bit.ly/3UO4yvD Register for free on Market-Scope.com to read more ophthalmic news: https://buff.ly/3mmLOlG #Ophthalmology #Ophthalmic #News #Revenues #Cataract #Glaucoma #Retina #Refractive #Cornea #Surgical #Pharma

Market Scope estimates that nearly 9,500 United States ophthalmologists perform cataract surgery. While the number of procedures each surgeon performs varies significantly, nearly 70 percent perform less than 200 annual surgeries, over 10 percent perform more than 400 annual procedures, and a small percentage of ultra-high-volume surgeons perform more than 800 annual procedures. To provide a geographic analysis of the conventional and premium cataract surgery opportunity in 85 US metropolitan areas, Market Scope’s “2024 United States Cataract Atlas” examines how many of these high-volume surgeons are in each metro, along with procedure volumes, premium penetration rates, population age distribution, patient income/buying power, overall health statistics, and population density. Companies often use this data throughout the development and commercialization processes to identify ideal clinical trial locations, develop launch strategies, define sales territories, allocate resources, and optimize sales and marketing initiatives. Practices also often use this data to determine market potential, identify expansion opportunities, and benchmark performance. To learn more about this report and request a sample: ?? https://bit.ly/24CtAtlas ?? [email protected] #Premium #CataractSurgery #CataractSurgeons #Prcoedures #IOLs #PCIOLs #Ophthalmology #MarketData #TerritoryAnalysis #UnitedStates

Weekly Ophthalmic News Update – the latest news & trends you need to know: Astellas Pharma Withdraws EU Marketing Application for Avacincaptad Pegol in GA: https://bit.ly/3YzdCFV Q3-2024 Ophthalmic Revenue Roundup for Regeneron, Bausch + Lomb, and Novartis: https://bit.ly/4ecBLaV VABYSMO? (faricimab-svoa) Improved Vision in Underrepresented Populations with DME in Elevatum Study: https://bit.ly/4hxTNY4 Michelle Tarver, MD, PhD, an Ophthalmologist, Named Director of FDA’s CDRH: https://bit.ly/4fnHUSK NovaBay Pharmaceuticals Receives Higher Asset Purchase Bid from RVL Pharmaceuticals-Affiliated Company: https://bit.ly/4fPxU55 Alkeus Pharmaceuticals, Inc.’ Oral Gildeuretinol for GA Shows Positive Topline Results in Phase III: https://bit.ly/3NW32nr RevOpsis Therapeutics Awarded $1.8 Million NEI Grant to Advance Retinal Candidate RO-104: https://bit.ly/3AD3fbX Korean Companies GC Biopharma (GC???), Novelty Nobility Inc. to Collaborate on GA Drug Discovery: https://bit.ly/3UxPIt9 Register for free on Market-Scope.com to read more ophthalmic news: https://buff.ly/3mmLOlG #Ophthalmology #Ophthalmic #News #Revenues #Cataract #Glaucoma #Retina #Refractive #Cornea #Surgical #Pharma

Market Scope projects that over 10 million premium cataract surgical procedures will be performed globally in 2024, generating manufacturer product revenue of over $3 billion. By 2029, these premium procedures are expected to grow to 14 million procedures and surpass $5 billion in manufacturer revenue. To provide competitors with a complete understanding of the opportunities in top markets, we have thoroughly analyzed 13 countries?—?the United States, China, Japan, Brazil, Germany, Canada, South Korea, Australia, India, France, Spain, United Kingdom, and Italy?—?that account for over 80 percent of global premium cataract surgical procedures. Each of these countries present a unique set of opportunities and challenges, which are all analyzed and outlined in Market Scope’s “2024 Premium Cataract Surgery Market Report.” The below figure allocates global premium cataract surgical procedures for each of these key countries. The United States accounts for nearly 3.4 million procedures and represents one third of global PCS procedures. While Australia accounts for the least procedures among these 13 countries, it has the highest premium penetration. China and India are expected to show the greatest yearly growth in procedures. The newly published “2024 Premium Cataract Surgery Market Report” provides detailed insights into these top 13 most important markets in the world. For each of these countries, this analysis includes the number of procedures by type; manufacturer and provider revenue and market share; the elderly population, economics, health care systems, and reimbursement; the providers offering premium procedures; and opinion-leading surgeons. The report focuses on eight premium cataract segments: toric IOLs, presbyopia-correcting IOLs, intermediate optimized (monofocal plus) IOLs, adjustable IOLs, femtosecond laser-assisted cataract surgery (FLACS), FLACS arcuate incisions, manual corneal incisions, and LASIK vision correction described as IOL enhancements (referred to in the report as LASIK IOL enhancements). To learn more about this report and request a sample: ?? https://bit.ly/24PCS ?? [email protected] #PremiumCataractSurgery #CataractSurgery #Prcoedures #IOLs #PCIOLs #Toric #FLACS #AdjustableIOLs #Ophthalmology #MarketData

Weekly Ophthalmic News Update – the latest news & trends you need to know: Pine Pharmaceuticals Stops Compounding IVT Avastin, Creating Concerns Over Shortage: https://bit.ly/3YiADN4 Q3-2024 Ophthalmic Revenue Roundup for Roche and Johnson & Johnson | Vision: https://bit.ly/3YHizOf US FDA Accepts NDA For LENZ Therapeutics’ Presbyopia Drop Candidate: https://bit.ly/40nPTe5 Ocuphire Pharma Acquires Opus Genetics, Will Operate Under Opus Name: https://bit.ly/4hgtcP4 ARPA-H Seeks Proposals for Tear Duct-Based Diagnostic System, Plus Custom Dosing Platform: https://bit.ly/4hltaFH Preliminary Results Show Science's Prima Implant Allows for Functional Vision in Advanced GA Patients: https://bit.ly/4e4EjI3 Grifols, #BARDA Partner on Ocular Immunoglobulin Drops for Sulfur Mustard Exposure: https://bit.ly/4hkTNL1 Corza Medical Launches Onatec Ophthalmic Microsurgical Suture Portfolio: https://bit.ly/3Ai9Vfy Register for free on Market-Scope.com to read more ophthalmic news: https://buff.ly/3mmLOlG #Ophthalmology #Ophthalmic #News #Revenues #Cataract #Glaucoma #Retina #Refractive #Cornea #Surgical #Pharma

Market Scope estimates that ophthalmic procedures in the Europe’s five largest ophthalmic markets — France, Germany, Italy, Spain, and the United Kingdom — will total over 17 million in 2024 and reach nearly 19 million by 2029. The most common procedures will be cataract surgeries and IVT injections, but glaucoma laser surgery is expected to grow at the highest rate. Several key trends will shape the ophthalmic market in these countries during the next five years, such as the aging population, increased regulation, rising health care costs and reimbursements, technological innovation and advances in treating diseases and health conditions, ongoing efforts to improve the efficiency of eye care services, changing roles for optometrists and ophthalmologists, and the paths patients take to obtain care. Market Scope’s new “2024 European Five Ophthalmic Market Report” analyzes the ophthalmic market in France, Germany, Italy, Spain, and the United Kingdom — discussing important trends and key factors for future success in 11 ophthalmic submarkets. The report includes forecasts of disease prevalence, numbers of treatments, and technologies used in treatments. It profiles ophthalmic companies in the five markets, provides analysis of current markets, and offers five-year forecasts of market performance. To learn more about this report and request a sample: ?? https://bit.ly/24E5MR ?? [email protected] #Ophthalmology #OphthalmicMarket #Europe #France #Germany #Italy #Spain #UnitedKingdom #MarketData #MarketIntelligence

Weekly Ophthalmic News Update – the latest news & trends you need to know: Bausch + Lomb Gains US FDA Approval of enVista Envy Trifocal IOL: https://bit.ly/4eO9FE0 Spinogenix, Inc. Unveils Glaucoma Program to Evaluate Once-Daily Neuroprotective Pill: https://bit.ly/3C2q9K5 Eyenuk, Inc., American Academy of Ophthalmology Collaborate to Offer AI-Driven DR Screening for Underserved Patients in Delaware: https://bit.ly/4fdnU5i US FDA Grants 510(k) Clearance to Flex Module for Heidelberg Engineering's Spectralis OCT: https://bit.ly/3Ydmv7U Orasis Pharmaceuticals Licenses #Qlosi Presbyopia Drops to #Optus in Korea for $18 Million, Plus Royalties: https://bit.ly/3NxUumj Nicox and Soleus Capital Management, L.P. Sign $16.5 Million Deal for #Vyzulta Royalties, Equity Financing: https://bit.ly/3UhsR4M Cure Blindness Project Expands Sight-Saving Care to Six New Countries: https://bit.ly/3zXxTwB LENSAR, Inc. Marks 1 Million Procedures Using its Femtosecond Cataract Lasers: https://bit.ly/3BQh7jj EU Grants Orphan Drug Status to Theriva Biologics, Inc.'s Retinoblastoma Candidate: https://bit.ly/3A8mCJJ Register for free on Market-Scope.com to read more ophthalmic news: https://buff.ly/3mmLOlG #Ophthalmology #Ophthalmic #News #Revenues #Cataract #Glaucoma #Retina #Refractive #Cornea #Surgical #Pharma